SIETES :: 92793 citas

Resultados de la búsqueda por PRESCRIPCIÓN REFINAR BÚSQUEDA

1.

Reeve E, Low L-F, Hilmer SN. Attitudes of older adults and caregivers in Australia toward deprescribing. J Am Geriatr Soc 2019;67:junio. [Ref.ID 103159]

2.

Montero-Odasso M, Sarquis-Adamson Y, Song HY, Bray NW, Pieruccini-Faria F, Speechley M. Polypharmacy, gait performance, and falls in community-dwelling older adults. Results from the Gait and Brain Study. J Am Geriatr Soc 2019;67:junio. [Ref.ID 103158]

3.

Anónimo. Managing medication . . . and other stories. BMJ 2019;365:l2363. [Ref.ID 103154]

4.

Samper E. La absurda historia del ibuprofeno de 600mg y el paracetamol de 1gr. eldiario.es 2019:31 de mayo. [Ref.ID 103127]

5.

Booth CM, Detsky AS. From the $80 hamburger to managing conflicts of interest with the pharmaceutical industry. BMJ 2019;365:3 de mayo. [Ref.ID 103106]

6.

Hedenmalm K, Slattery J, Skibicka-Stepien I, Kurz X, Morales D. Prescribing patterns of tramadol in adults in IMS® primary care databases in France and Germany between 1 January 2006 and 30 June 2016. Eur J Clin Pharmacol 2019;75:5. [Ref.ID 103092]

7.

Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]

8.

McGreal C. Primera condena penal al director de una farmacéutica por su papel en la epidemia de opiáceos que asola EEUU. eldiario.es 2019:3 de mayo. [Ref.ID 103089]

9.

Iacobucci G. NHS prescribed record number of antidepressants last year. BMJ 2019;364:29 de marzo. [Ref.ID 103088]

10.

Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ 2019;365:4 de abril. [Ref.ID 103086]

11.

Torjesen I. Pregabalin and gabapentin: what impact will reclassification have on doctors and patients?. BMJ 2019;364:11 de marzo. [Ref.ID 103081]

12.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

13.

Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179:mayo. [Ref.ID 103073]

14.

Brownlee S, Garber J. Overprescribed: High cost isn’t America’s only drug problem. STAT Daily Recap 2019:2 de abril. [Ref.ID 103070]

15.

Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

16.

Chua K-P, Fischer MA, Linder JA. Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study. BMJ 2019;364:16 de enero. [Ref.ID 103048]

17.

Anónimo. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). U.S. Food and Drug Administration 2019:21 de febrero. [Ref.ID 103045]

18.

Avery AJ, Bell BG. Rationalising medications through deprescribing. BMJ 2019;364:7 de febrero. [Ref.ID 103031]

19.

Alexander M. Los calmantes opioides no funcionan para el dolor crónico. ¿Por qué los seguimos recetando?. eldiario.es 2019:27 de enero. [Ref.ID 103017]

20.

Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M. Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses. JAMA Network Open 2019;2:18 de enero. [Ref.ID 103009]